78% of Cancer Disparities Researchers Can't Apply for Funding Amid $317M in Grant Cuts

The American Association for Cancer Research (AACR) has released a stark report revealing that federal funding freezes and cancellations have crippled cancer disparities research, with 93% of surveyed scientists in the field reporting disruption to their work. The report, published on July 15, 2026, draws on a survey of 122 researchers—from professors to graduate students—and comes at a time when persistent cancer outcome gaps demand urgent attention. Rural Americans are 18% more likely to die from cancer overall, and Black women face a 35% higher breast cancer mortality rate than white women, underscoring why these studies matter. Yet, in the first half of 2025, the National Cancer Institute (NCI) alone canceled 181 grants totaling more than $317 million, many of which were specifically investigating disparities. These cuts were part of a broader retraction of thousands of National Institutes of Health (NIH) grants following an executive order in January 2025, as documented by the non-profit Grant Witness. The consequences are not abstract: 78% of researchers reported being unable to apply for new funding, and 59% said ongoing projects were interrupted. In some cases, clinical trials were halted mid-treatment, abruptly cutting off patients from experimental therapies. Mariana Stern, chair of the AACR report committee, noted that these mid-trial stoppages meant patients suddenly stopped receiving treatments they had been getting. The funding loss has disproportionately hit initiatives addressing the very disparities that have long plagued oncology care. The JAMA Oncology data, published in November 2025, quantified the NCI cancellations, showing a concentrated attack on grants with titles hinting at race, ethnicity, or rural health. The downstream effects are already cascading through academic medical centers, biotech collaborations, and community outreach programs. For instance, researchers who lose NIH funding often cannot sustain the personnel or infrastructure needed to continue longitudinal studies, creating data gaps that will take years to fill. Early-career scientists and investigators from underrepresented groups are particularly vulnerable, as they often rely on federal grants to build their reputations and cannot easily pivot to industry funding. The timing is especially cruel because cancer disparities had been narrowing thanks to decades of targeted research, yet the AACR report warns that progress may reverse without immediate policy correction. In addition to the direct health equity toll, the freeze sends a chilling signal to the global research community, potentially diverting talent away from a field that is already under-resourced. The report’s survey also found that 59% of those who lost funding attributed the gap directly to NIH cuts, indicating that the NCI is not the only institute pulling back. The future of precision medicine—which depends on diverse population data to develop effective treatments—is now uncertain. Advocates argue that restoring these grants is not just a matter of scientific integrity but of economic and moral urgency: every cancer death avoidable through research is a loss the healthcare system cannot afford. While the Biden or subsequent administrations have not yet signaled a reversal, the AACR recommends immediate legislative action to insulate science from political volatility. In the interim, patient advocacy groups are stepping in with stopgap funds, but they cannot replicate the billions the NIH provided. The report makes clear that without a stable funding environment, cancer disparities will widen, and the burden will fall disproportionately on the most marginalized communities.